Abstract
Studies of dipeptidyl peptidase-4 inhibitors (DPP-4i) report heterogeneous effects on endothelial function in patients with type 2 diabetes. This study assessed the effects of the DPP-4i linagliptin (LINA) vs the sulfonylurea glimepiride (GLIM) and placebo (PBO) on measures of macro- and
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
